Literature DB >> 28104311

Comprehensive Profiling of the Androgen Receptor in Liquid Biopsies from Castration-resistant Prostate Cancer Reveals Novel Intra-AR Structural Variation and Splice Variant Expression Patterns.

Bram De Laere1, Pieter-Jan van Dam1, Tom Whitington2, Markus Mayrhofer2, Emanuela Henao Diaz3, Gert Van den Eynden4, Jean Vandebroek5, Jurgen Del-Favero6, Steven Van Laere1, Luc Dirix7, Henrik Grönberg2, Johan Lindberg8.   

Abstract

BACKGROUND: Expression of the androgen receptor splice variant 7 (AR-V7) is associated with poor response to second-line endocrine therapy in castration-resistant prostate cancer (CRPC). However, a large fraction of nonresponding patients are AR-V7-negative.
OBJECTIVE: To investigate if a comprehensive liquid biopsy-based AR profile may improve patient stratification in the context of second-line endocrine therapy. DESIGN, SETTING, AND PARTICIPANTS: Peripheral blood was collected from patients with CRPC (n=30) before initiation of a new line of systemic therapy. We performed profiling of circulating tumour DNA via low-pass whole-genome sequencing and targeted sequencing of the entire AR gene, including introns. Targeted RNA sequencing was performed on enriched circulating tumour cell fractions to assess the expression levels of seven AR splice variants (ARVs). OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Somatic AR variations, including copy-number alterations, structural variations, and point mutations, were combined with ARV expression patterns and correlated to clinicopathologic parameters. RESULTS AND LIMITATIONS: Collectively, any AR perturbation, including ARV, was detected in 25/30 patients. Surprisingly, intra-AR structural variation was present in 15/30 patients, of whom 14 expressed ARVs. The majority of ARV-positive patients expressed multiple ARVs, with AR-V3 the most abundantly expressed. The presence of any ARV was associated with progression-free survival after second-line endocrine treatment (hazard ratio 4.53, 95% confidence interval 1.424-14.41; p=0.0105). Six out of 17 poor responders were AR-V7-negative, but four carried other AR perturbations.
CONCLUSIONS: Comprehensive AR profiling, which is feasible using liquid biopsies, is necessary to increase our understanding of the mechanisms underpinning resistance to endocrine treatment. PATIENT
SUMMARY: Alterations in the androgen receptor are associated with endocrine treatment outcomes. This study demonstrates that it is possible to identify different types of alterations via simple blood draws. Follow-up studies are needed to determine the effect of such alterations on hormonal therapy.
Copyright © 2017 European Association of Urology. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  AR splice variants; AR-V7; Androgen receptor; Castration-resistant prostate cancer; Circulating tumour DNA; Endocrine treatment; Structural variation

Mesh:

Substances:

Year:  2017        PMID: 28104311     DOI: 10.1016/j.eururo.2017.01.011

Source DB:  PubMed          Journal:  Eur Urol        ISSN: 0302-2838            Impact factor:   20.096


  50 in total

1.  Androgen Receptor Burden and Poor Response to Abiraterone or Enzalutamide in TP53 Wild-Type Metastatic Castration-Resistant Prostate Cancer.

Authors:  Bram De Laere; Prabhakar Rajan; Henrik Grönberg; Luc Dirix; Johan Lindberg
Journal:  JAMA Oncol       Date:  2019-07-01       Impact factor: 31.777

Review 2.  Role of androgen receptor splice variants, their clinical relevance and treatment options.

Authors:  S Wach; H Taubert; M Cronauer
Journal:  World J Urol       Date:  2019-01-19       Impact factor: 4.226

Review 3.  Allosteric alterations in the androgen receptor and activity in prostate cancer.

Authors:  Takuma Uo; Stephen R Plymate; Cynthia C Sprenger
Journal:  Endocr Relat Cancer       Date:  2017-09       Impact factor: 5.678

Review 4.  cfRNAs as biomarkers in oncology - still experimental or applied tool for personalized medicine already?

Authors:  Tomasz Kolenda; Kacper Guglas; Dawid Baranowski; Joanna Sobocińska; Magda Kopczyńska; Anna Teresiak; Renata Bliźniak; Katarzyna Lamperska
Journal:  Rep Pract Oncol Radiother       Date:  2020-08-11

Review 5.  Development and Application of Liquid Biopsies in Metastatic Prostate Cancer.

Authors:  Gareth J Morrison; Amir Goldkorn
Journal:  Curr Oncol Rep       Date:  2018-03-23       Impact factor: 5.075

6.  Diverse AR Gene Rearrangements Mediate Resistance to Androgen Receptor Inhibitors in Metastatic Prostate Cancer.

Authors:  Yingming Li; Rendong Yang; Christine M Henzler; Yeung Ho; Courtney Passow; Benjamin Auch; Suzanne Carreira; Daniel Nava Rodrigues; Claudia Bertan; Tae Hyun Hwang; David A Quigley; Ha X Dang; Colm Morrissey; Michael Fraser; Stephen R Plymate; Christopher A Maher; Felix Y Feng; Johann S de Bono; Scott M Dehm
Journal:  Clin Cancer Res       Date:  2020-01-13       Impact factor: 12.531

Review 7.  Androgen Receptor Rearrangement and Splicing Variants in Resistance to Endocrine Therapies in Prostate Cancer.

Authors:  Yeung Ho; Scott M Dehm
Journal:  Endocrinology       Date:  2017-06-01       Impact factor: 4.736

Review 8.  Rationale for the development of alternative forms of androgen deprivation therapy.

Authors:  Sangeeta Kumari; Dhirodatta Senapati; Hannelore V Heemers
Journal:  Endocr Relat Cancer       Date:  2017-05-31       Impact factor: 5.678

9.  Plasma Androgen Receptor Copy Number Status at Emergence of Metastatic Castration-Resistant Prostate Cancer: A Pooled Multicohort Analysis.

Authors:  Anuradha Jayaram; Anna Wingate; Daniel Wetterskog; Vincenza Conteduca; Daniel Khalaf; Mansour Taghavi Azar Sharabiani; Fabio Calabrò; Lorraine Barwell; Susan Feyerabend; Enrique Grande; Alberto Martinez-Carrasco; Albert Font; Alfredo Berruti; Cora N Sternberg; Rob Jones; Florence Lefresne; Marjolein Lahaye; Shibu Thomas; Shilpy Joshi; Dong Shen; Deborah Ricci; Michael Gormley; Axel S Merseburger; Bertrand Tombal; Matti Annala; Kim N Chi; Ugo De Giorgi; Enrique Gonzalez-Billalabeitia; Alexander W Wyatt; Gerhardt Attard
Journal:  JCO Precis Oncol       Date:  2019-09-24

Review 10.  The value of cell-free DNA for molecular pathology.

Authors:  Caitlin M Stewart; Prachi D Kothari; Florent Mouliere; Richard Mair; Saira Somnay; Ryma Benayed; Ahmet Zehir; Britta Weigelt; Sarah-Jane Dawson; Maria E Arcila; Michael F Berger; Dana Wy Tsui
Journal:  J Pathol       Date:  2018-03-12       Impact factor: 7.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.